Terminal Sterilisation Envelope and Endotoxin Control for Parenteral Presentation

Terminal sterilisation of parenteral presentations represents the highest specification-demanding route among the seven listed dosage forms. Nainiu Fanchu Powder Veterinary Grade API destined for sterile injectable manufacturing is subjected to a multi-stage sequence beginning with dissolution in Water for Injection (WFI) conforming to Ph. Eur. 5.1.1 at a concentration range of 50–200 mg/mL. The resulting bulk solution is adjusted to pH 6.0–7.5 using 0.1 M hydrochloric acid or 0.1 M sodium hydroxide, both of pharmacopoeial grade, before clarification through a 0.45 µm polypropylene pre-filter followed by sterilising-grade filtration through a validated 0.22 µm PVDF membrane cartridge with a bubble point of at least 1.2 bar per ASTM F838-20. Endotoxin burden in the finished sterile solution is maintained below 0.5 EU/mg per USP <85>, with LAL testing executed on every sub-lot. Terminal sterilisation is conducted in a saturated steam autoclave at 121°C for 15 minutes (F0 ≥ 8, Ph. Eur. 5.1.1 method B), unless thermal degradation profiling mandates aseptic filtration alone, in which case Grade A (ISO 5) laminar flow filling with concurrent media fill validation is required. Particulate matter in the finished container is controlled to USP <788> limits (NMT 6000 particles ≥ 10 µm and NMT 600 particles ≥ 25 µm per container). Container-closure integrity is verified by dye ingress testing per USP <1207>. Storage of the finished sterile solution in Type I amber borosilicate glass vials at 15–25°C is specified to mitigate photodegradation of the aromatic constituents. Batch sizes for sterile injectable production typically range from 50 L to 500 L, processed in 316L stainless steel compounding vessels equipped with bottom-mounted magnetic stirrers to avoid dead-leg contamination. The vial filling line operates at speeds of 2000–8000 units/hour depending on fill volume (50 mL or 100 mL), with in-process weight checks performed every 15 minutes targeting a fill volume tolerance of ± 3%. Lyophilisation is not routinely employed for this API class; however, when enhanced shelf-life beyond 24 months is specified, a lyophilisation cycle at −40°C primary drying and +25°C secondary drying (vacuum ≤ 0.1 mbar) produces a cake residue of NMT 2% moisture, enabling a 36-month expiry assignment with supporting ICH Q1E data. The selection of rubber stopper composition is restricted to bromobutyl formulations with low extractable profiles to prevent interaction with alkaline hydrolysable groups. Finished product types are sterile injectable solutions in 50 mL and 100 mL Type I glass vials with bromobutyl rubber closures and aluminium flip-off caps.

At the feed mill scale, incorporation of Nainiu Fanchu Powder Veterinary Grade API into complete dairy TMR premixes follows a step-up blending protocol specified under FAMI-QS and GMP+ BA2 feed safety assurance schemes, with the final premix registered under EU Regulation 1831/2003 where applicable. The undiluted API powder is first blended with a mineral or botanical carrier—limestone flour, rice hulls, or dried sugar beet pulp—at a ratio of 1:10, followed by a second dilution to 1:100 in a 500 kg ribbon mixer, and finally incorporated into the production-scale 2-tonne horizontal ribbon mixer at a target inclusion of 0.05–0.2% w/w in the complete feed. Homogeneity testing per EU Regulation 152/2009 method B requires a coefficient of variation (CV) below 5% across 10 sampling points, with the sampling plan including three points from the mixer discharge gate, three from the bagging line, and four from stored bagged product to account for segregation during handling. Bulk density of the API powder measured by a 1 L cylinder method (ISO 697:1981) falls within 0.45–0.65 g/cm³, and when blended with low-density botanical carriers, electrostatic charge accumulation is mitigated by the addition of 1–2% refined vegetable oil to the ribbon mixer during the final 2 minutes of mixing. Carryover control is mandatory under FAMI-QS; residual active substance in subsequent non-medicated batches is maintained below 2% of the target dose, verified by rinsate swab testing at the mixer wall, discharge auger, and bagging spout. Particle size distribution of the API powder is specified at D50 150–300 µm and D90 below 500 µm by laser diffraction (ISO 13320:2020), with sieve cuts above 800 µm rejected due to segregation tendency in TMR mixing wagons. The ribbon mixer is typically operated at 40–60 RPM with a mixing time of 8–12 minutes; over-mixing beyond 15 minutes increases the risk of particle attrition and may elevate fine particle fraction, which in turn increases dust generation and electrostatic adhesion to mixer walls. The bagging line utilises a horizontal form-fill-seal machine with nitrogen flushing to displace oxygen headspace and reduce oxidative stress on unsaturated carrier oils. Each batch of premix requires a Certificate of Analysis including active substance assay, moisture content, aerobic plate count (NMT 10⁵ CFU/g per USP <2021>), and Salmonella absence (per ISO 6579-1:2017). Storage stability in multilayer paper bags with LDPE inner liner is confirmed at 25°C / 60% RH for 24 months per VICH GL21, with moisture ingress limited to NMT 0.5% w/w per year. The finished premix format is a 20 kg bag for commercial dairy farms and a 500 kg bulk bag for feed mill integration. Inclusion rate at the farm level for TMR preparation is determined by the registered feeding guidelines and the target daily dose per adult dairy cow, typically 50–150 g of premix per cow per day delivered via the mixing wagon.

What Determines Capping Propensity During Direct Compression of Ruminant GI Function Modulators?

Direct compression of Nainiu Fanchu Powder Veterinary Grade API into oral tablets for cattle is constrained by the powder's viscoelastic recovery characteristics, which induce capping when the compression force exceeds the formulation's plastic deformation threshold. Formulation development studies conducted on single-station instrumented tablet presses (Korsch XP 1, 10 kN load cell) demonstrate that the API alone exhibits a compactibility below 60 N at a compression pressure of 120 MPa when tested per USP <1062>, necessitating the inclusion of microcrystalline cellulose (MCC grade PH102) at 30–45% w/w as a plastic binder, with lactose monohydrate (200 mesh) serving as a brittle filler at 15–25% w/w. Magnesium stearate is restricted to 0.5–1.0% w/w because higher levels significantly delay disintegration (USP <701>) beyond the 15-minute pharmacopoeial limit. The final tablet formulation typically contains 45–65% w/w API, producing a 1000 mg tablet with hardness 60–120 N (tested per Ph. Eur. 2.9.8), friability below 1% per USP <1216>, and disintegration not exceeding 15 minutes in 37°C distilled water. Film coating with hydroxypropyl methylcellulose (HPMC, 15 cP grade) at 2–3% weight gain provides a moisture barrier for tablets stored at RH > 60% and masks the bitter botanical constituents. Pre-compression force is set at 2–4 kN with main compression at 8–15 kN on a rotary press (FETTE 2090, 30 stations, 100,000 tablets/hour). The powder blend is subjected to lubrication for exactly 3–5 minutes; excess lubrication beyond 10 minutes produces measurable reductions in tensile strength due to shear-induced coating of MCC surfaces. Direct compression is selected as the default manufacturing route because the API powder's particle morphology permits adequate die filling when flow aid (colloidal silicon dioxide 0.25–0.5% w/w) is incorporated, though environments with RH below 30% may necessitate 1% w/w water addition to the pre-blend to suppress static charge during hopper discharge. Finished product types are 500 mg and 1000 mg uncoated or film-coated tablets packed in blister strips of 10 units.

Establishing Granulation Endpoint Parameters for Fluid-Bed Drying at Variable Ambient Humidity

When wet granulation is employed because the API powder's poor flowability (Carr index above 25 per USP <1174>) prevents direct compression or uniform capsule filling, the process sequence utilises a 250 L high-shear granulator (GEA Aeromatic-Fielder PMA series) with granulating liquid consisting of purified water or 5% w/v polyvinylpyrrolidone (PVP K29/32) solution at a liquid-to-solid ratio of 0.2–0.3, impeller speed ramped from 150 to 300 RPM, and chopper engaged at 1500 RPM during the final 2 minutes. Granulation endpoint is determined by power consumption inflection (GLATT Real-Time Moisture Analyser) correlated with a target moisture of 8–12% w/w. The wet mass is discharged through a 3 mm sieve and transferred to a fluid-bed dryer equipped with a 30 µm filter bag; inlet air temperature is maintained at 50–60°C, with drying continued until final moisture reaches 2–4% w/w (measured by loss-on-drying at 105°C per USP <731>). The dried granules are sized through a 14–60 mesh sieve stack (1.40 mm to 0.25 mm), rejecting oversized material for dry milling and undersized material for re-granulation. When ambient relative humidity exceeds 60%, the granulation endpoint requires adjustment: the liquid-to-solid ratio is reduced by 10% and the drying time extended by 20% to compensate for the increased moisture load in the inlet air. The API addition ratio in the final granule formulation is 30–50% w/w, with sucrose and lactose monohydrate as bulking agents and povidone as binder. The finished granules are packed in 100 g or 500 g sachets made from aluminium foil laminate with a water vapour transmission rate below 0.5 g/m²/day (ASTM F1249-20) to maintain API stability at 25°C / 60% RH for 24 months per VICH GL21. Compliance for the granule presentation is anchored to USP <795> for nonsterile compounding, Ph. Eur. 2.9.12 for flowability, and VICH GL11 for impurity profiling. Published data on the compressibility of granules produced with this specific API at scale remains limited beyond the 250 L batch size threshold.

The direct oral powder presentation for drench administration is manufactured by low-shear tumble blending in a 500 L V-blender at 15 RPM for 20 minutes, combining Nainiu Fanchu Powder Veterinary Grade API at 10–25% w/w with sodium bicarbonate (USP grade) as alkalising diluent and sucrose (NF grade) as palatability agent. The mixture is passed through a 60 mesh (250 µm) sieve to break up soft agglomerates, then packaged in 250 g and 1 kg HDPE jars fitted with 33 mm polypropylene caps and a 2 g silica gel desiccant canister to maintain moisture below 0.5% w/w during storage. Reconstitution instructions specify dispersing the powder in 5–10 L of warm water (35–40°C) per adult cow dose immediately before administration via stomach tube or dose syringe. Compliance for the powder presentation references USP <795> for nonsterile compounding and VICH GL11 for impurity limits, with terminal finished product types being 250 g and 1 kg HDPE jars. Published data on the bioavailability equivalence of this presentation relative to the granule form is limited.

When High-RH Processing Constrains Capsule Fill Weight Uniformity

Capsule filling of the API powder for individual animal dosing employs a semi-automatic encapsulator (CAP8, 8000 capsules/hour) with size 0, 1, or 2 HPMC or gelatin capsules, targeting a fill weight of 250–500 mg. The dry blend comprises 50–70% w/w API with lactose monohydrate and 0.5% magnesium stearate. Fill weight uniformity per USP <1163> requires acceptance value below 15. When ambient RH exceeds 60%, the API powder's hygroscopic constituents absorb moisture, reducing flow and causing fill weight variance; pre-drying at 50°C for 2 hours in a tray dryer restores acceptable flow characteristics. Disintegration testing per USP <2040> confirms capsule rupture within 30 minutes. Finished product types are size 0, 1, and 2 capsules in HDPE bottle counts of 100 and 500.

Preparation of the oral solution presentation requires dissolving Nainiu Fanchu Powder Veterinary Grade API in purified water at a concentration of 5–15% w/v with the addition of sodium benzoate (0.1–0.2% w/v) and potassium sorbate (0.05–0.1% w/v) as antimicrobial preservatives, conforming to antimicrobial effectiveness testing per USP <51>. The solution pH is adjusted to 5.5–6.5 with citric acid monohydrate, and viscosity is confirmed below 100 cP at 25°C (Brookfield LV viscometer, spindle 1, 60 RPM) to ensure compatibility with automatic drenching equipment. The packaged product in 500 mL or 1 L amber PET bottles is stable for 18 months at 15–25°C when stored upright in the dark; inversion or horizontal storage during transport may result in particulate settling, and the product should be re-shaken before use. Compliance for the oral solution references USP <795> for nonsterile compounding, VICH GL18 for residual solvents, and Ph. Eur. 5.1.3 for pharmaceutical water quality. The downstream production process utilises a 500 L stainless steel mixing tank with bottom-mounted propeller agitator at 120 RPM, followed by 100 µm in-line straining before filling on a 2-head volumetric bottling line operating at 3000 bottles/hour. Finished product types are 500 mL and 1 L amber PET bottles with tamper-evident dosing cup closures.